AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 151 min read$CYTK

Blum Robert I sold $551K of CYTK

Blum Robert I (President & CEO) sold 7,500 shares of CYTOKINETICS INC (CYTK) at $73.44 ($0.55M total) on 2026-09-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Blum Robert I
Published Sep 15, 2026, 9:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 9:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CYTK
Neutral
medium confidence
Mentioned
$CYTK
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CYTKNeutralLow
01

Why it matters

The transaction reduces insider ownership but does not indicate immediate strategic change.

02

Market read

Provides fresh data on insider holdings for traders monitoring Cytokinetics.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 4/10Novelty 6/10Timing: post‑market filing on 2026‑09‑14

Background

Form 4 filings disclose insider transactions; a 10b5-1 plan sale is pre‑arranged and often routine.

Company-level read

Ticker impact

$CYTKNeutralMedium confidence
Context

President & CEO Robert Blum sold 7,500 shares for $550,800 via a 10b5-1 plan, reducing his stake to 377,820 shares.

Expected impact

Potential minor downward pressure in the short term.

Evidence & confidence

The sale is under $1M and executed under a pre-arranged plan, indicating routine liquidity rather than loss of confidence.

Market effects

Sector

Minimal effect on the biotech sector; typical insider sales are common.

Regional

Negligible impact on broader market indices.

Global

Limited to investors tracking Cytokinetics.

Counterpoint

What could challenge this read

The sale could be interpreted as a signal of upcoming dilution or concerns about near‑term performance.

Key entities

  • Executive
    Robert Blum

    President & CEO of Cytokinetics Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CYTK insider trading history →

Related articles

OCT 13
$CYTKHigh

Cytokinetics Highlights Exercise Capacity, Responder Data For Aficamten In NHCM At HFSA 2026

Cytokinetics (CYTK) presented data from the ACACIA-HCM trial at the HFSA 2026 meeting, showing aficamten improved exercise performance and clinical outcomes in non-obstructive HCM patients. The drug demonstrated significant benefits in exercise capacity, symptom relief, and safety, with 53% of patients showing improvements across multiple domains. CYTK reported a Q2 2026 net loss of $198.8M and $25.3M in aficamten revenue, with cash reserves of $1.7B.

rttnews.com2 min
OCT 12
$CYTKMed

Cytokinetics presents additional aficamten data from trial

Cytokinetics (CYTK) presented additional data from its ACACIA-HCM trial at the Heart Failure Society of America Annual Scientific Meeting. Aficamten showed statistically significant improvements in exercise performance and clinical response in patients with non-obstructive hypertrophic cardiomyopathy. The company plans to submit a supplemental New Drug Application to the FDA this quarter for this indication.

uk.investing.com1 min
OCT 12
$CYTKMed

Serious heart failure events affected 4.7% taking aficamten, versus 1.2% on placebo.

Cytokinetics (CYTK) presented additional data from the ACACIA-HCM trial at the HFSA Annual Scientific Meeting. The study showed aficamten improved exercise performance and safety in non-obstructive HCM patients. Serious heart failure events occurred in 4.7% of aficamten patients vs. 1.2% on placebo. The company plans to submit a supplemental New Drug Application to the FDA this quarter.

stocktitan.net4 min